1. Home
  2. RNTX vs NTZ Comparison

RNTX vs NTZ Comparison

Compare RNTX & NTZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNTX
  • NTZ
  • Stock Information
  • Founded
  • RNTX 2001
  • NTZ 1959
  • Country
  • RNTX United States
  • NTZ Italy
  • Employees
  • RNTX N/A
  • NTZ N/A
  • Industry
  • RNTX Biotechnology: Pharmaceutical Preparations
  • NTZ Home Furnishings
  • Sector
  • RNTX Health Care
  • NTZ Consumer Discretionary
  • Exchange
  • RNTX Nasdaq
  • NTZ Nasdaq
  • Market Cap
  • RNTX 40.3M
  • NTZ 41.6M
  • IPO Year
  • RNTX N/A
  • NTZ 1993
  • Fundamental
  • Price
  • RNTX $1.45
  • NTZ $3.00
  • Analyst Decision
  • RNTX
  • NTZ
  • Analyst Count
  • RNTX 0
  • NTZ 0
  • Target Price
  • RNTX N/A
  • NTZ N/A
  • AVG Volume (30 Days)
  • RNTX 37.4K
  • NTZ 1.9K
  • Earning Date
  • RNTX 08-13-2025
  • NTZ 07-02-2025
  • Dividend Yield
  • RNTX N/A
  • NTZ N/A
  • EPS Growth
  • RNTX N/A
  • NTZ N/A
  • EPS
  • RNTX N/A
  • NTZ N/A
  • Revenue
  • RNTX N/A
  • NTZ $337,653,480.00
  • Revenue This Year
  • RNTX N/A
  • NTZ N/A
  • Revenue Next Year
  • RNTX N/A
  • NTZ N/A
  • P/E Ratio
  • RNTX N/A
  • NTZ N/A
  • Revenue Growth
  • RNTX N/A
  • NTZ N/A
  • 52 Week Low
  • RNTX $1.33
  • NTZ $2.81
  • 52 Week High
  • RNTX $4.40
  • NTZ $6.27
  • Technical
  • Relative Strength Index (RSI)
  • RNTX N/A
  • NTZ 31.63
  • Support Level
  • RNTX N/A
  • NTZ $3.25
  • Resistance Level
  • RNTX N/A
  • NTZ $3.32
  • Average True Range (ATR)
  • RNTX 0.00
  • NTZ 0.05
  • MACD
  • RNTX 0.00
  • NTZ -0.06
  • Stochastic Oscillator
  • RNTX 0.00
  • NTZ 0.00

About RNTX Rein Therapeutics Inc. Common Stock

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

About NTZ Natuzzi S.p.A.

Natuzzi SpA is an Italian firm that designs, manufactures, and sells contemporary and traditional leather and fabric-upholstered furniture. Its product portfolio includes sofas, loveseats, armchairs, sectional furniture, motion furniture and sofa beds, living room furnishings, and accessories. The company markets its products under several brands such as Natuzzi Italia, Private label, and Natuzzi Editions. Geographically, it derives a majority of its revenue from the United States of America and also has an international presence in Italy, Spain, the UK, China, and Other countries.

Share on Social Networks: